Journals / Hacettepe Journal of Biology and Chemistry / 2011 / Cilt: 39 - Sayı: 2

Ekstrakorporal afinite tedavisi

Extracorporeal affinity therapy

Pages
93–110
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this article, some interesting applications on extracorporeal affinity therapies for removal of toxic substances from human plasma are briefly reviewed.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Extracorporeal therapies are directed at the removal of potential toxic substances including bilirubin, pathogenic antibodies, various circulating immune-complexes, cholesterol, toxic metal ions, etc. from human plasma.
📊
Key Findings & Data:The conventional extracorporeal therapies including plasma exchange, hemodialysis, hemofiltration and hemoperfusion are non-selective techniques.
💡
Conclusion & Impact:In this article, some interesting applications on extracorporeal affinity therapies for removal of toxic substances from human plasma are briefly reviewed.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Extracorporeal therapies are directed at the removal of potential toxic substances including bilirubin, pathogenic antibodies, various circulating immune-complexes, cholesterol, toxic metal ions, etc. from human plasma. The conventional extracorporeal therapies including plasma exchange, hemodialysis, hemofiltration and hemoperfusion are non-selective techniques. In addition the requirement for plasma substitutes such as albumin is very high. Moreover, the dangers of hepatitis or immune reactions accompany these therapies while using plasma for plasma products. Today, one of the most promising procedures for extracorporeal therapy is specific affinity adsorption. Affinity carriers may be used in hemoperfusion system, where blood is directly perfused through the column filled with these carriers. This type of application is effective, simple and inexpensive. In this article, some interesting applications on extracorporeal affinity therapies for removal of toxic substances from human plasma are briefly reviewed.

Özet

Ekstrakorporal tedaviler bilirubin, patojenik antibadiler, dolaşımdaki çeşitli immün kompleksler, kolesterol, toksik metal iyonları gibi olası toksik maddelerin insan plazmasından uzaklaştırılmasına yöneliktir. Plazma değişimi, hemodiyaliz, hemofiltrasyon ve hemoperfüzyonu içeren geleneksel ekstrakorporal tedaviler seçici olmayan yöntemlerdir. Ayrıca, albümin gibi plazma desteklerine olan ihtiyaç oldukça fazladır. Dahası, plazma ve plazma destekleri kullanılırken hepatit veya immün reaksiyonların ortaya çıkma tehlikesi bulunmaktadır. Günümüzde ekstrakorporal tedavinin en umut verici uygulaması spesifik afinite adsorpsiyonudur. Afinite taşıyıcılar, kanın bu taşıyıcılarla doldurulmuş kolondan doğrudan geçirildiği hemoperfüzyon sisteminde kullanılabilir. Bu tür uygulama etkili, basit ve ucuzdur. Bu derlemede, ekstrakorporal tedavinin insan plazmasından toksik maddelerin uzaklaştırılması için kullanıldığı bazı ilginç uygulamalar kısaca verilmiştir.

🔖

Cite This Article

DENİZLİ, A. (2022). Ekstrakorporal afinite tedavisi. Hacettepe Journal of Biology and Chemistry, Cilt: 39 - Sayı: 2, 93–110. https://ajindex.com/articles/529235

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. E. Pişkin, A.S. Hoffman, Polymeric Biomaterials, NATO ASI Series, Martinus Nijhoff Publishers, Dordrecht, 1986
  2. S. Xia, N. Hodge, M. Laski, T.F. Wiesner, Middle molecule uremic toxin removal via hemodialysis augmented with an immunosorbent packed bed, Ind. Eng. Chem. Res., 49 (2010) 1359
  3. E. Behm, P. Ivanovich, H. Klinkmann, Selective and specific adsorbents for medical therapy, Int. J. Artif. Organs, 12 (1989) 1
  4. Y. Takenaka, Bilirubin adsorbent column for plasma perfusion, Therapeutic Apheresis, 2 (1998) 129
  5. K.H. Lee, J. Wendon, M. Lee, M.D. Costa, S.G. Lim, K.C. Tan, Predicting the decrease of conjugated bilirubin with extracorporeal albumin dialysis MARS using the predialysis molar ratio of conjugated bilirubin to albumin, Liver Transplantation, 8 (2002) 591
  6. J.D. Ostrow, Bile Pigments and Jaundice: Molecular, Metabolic and Medical Aspects, New York, Dekker, 1986
  7. C. Tiribelli, J.D. Ostrow, The molecular basis of bilirubin encephalopathy and toxicity, J. Hepatology, 43 (2005) 156
  8. X.X. Zhu, G.R. Brown and L.E. St-Pierre, Adsorption of bilirubin with polypeptide-coated resin, Biomat. Artif. Cells, Artif. Organs, 18 (1990) 75
  9. S. Sideman, L. Mor, D. Mordohovich, M. Mihich, O. Zinder and J.M. Brandes, In vivo hemoperfusion studies of unconjugated bilirubin removal by ion exchange resin, Trans. Am. Soc. Artif. Intern. Organs, 27 (1981) 434
  10. Y. Idezuki, M. Hamaguchi, S. Hamabe, H. Moriya, T. Nagashima, H. Watanabe, T. Sonoda, K. Teramoto, T. Kikuchi, H. Tanzawa, Removal of bilirubin and bile acid with a new anion exchange resin, Trans Am. Soc. Artif. Intern. Organs, 27 (1981) 428
  11. G.R. Brown, Oligo-peptide functionalized polymeric sorbents for bilirubin, Int. J. Biochromatogr., 1 (1994) 73
  12. T. Chandy, C.P. Sharma, Polylysine immobilized chitosan beads as adsorbents for bilirubin, Artif. Organs, 16 (1992) 568
  13. Z. Yamazaki, N. Inoue, T. Wada, T. Oda, K. Atsumi, K. Kataoka and Y. Fujisaki, Use of an AR-1 resin column to reduce bilirubin level in modified ascitic fluid, Trans. Am. Soc. Artif. Intern. Organs, 25 (1979) 480
  14. T. Morimoto, M. Matsushima, N. Sowa, K. Ide and S. Sawanishi, Plasma adsorption using bilirubinadsorbent materials as a treatment for patients with hepatic failure, Artif. Organs, 13 (1989) 447
  15. M.E. Avramescu, W.F.C. Sager, Z. Borneman, M. Wessling, Adsorptive membranes for bilirubin removal, J. Chromatogr. B., 803 (2004) 215
  16. Y. Yu, B. He, H. Gu, Adsorption of bilirubin by aminecontain